the major downstream RAS effectors PI3K, RAF and RAL–GEF and cytokine signaling pathways. Examples of clinical-stage small-molecule kinase inhibitors that target each signaling axis are also ...

These findings could pave the way for new treatment approaches for cancers driven by RAS mutations. Researchers at the ...

Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced ...

We played an important role in revealing the biochemical steps of the RAS-RAF-MAP kinase pathway. We discovered one of the major ways by which RAS oncogenes cause normal cells to become cancerous – ...

Candel Therapeutics (CADL) announced preclinical results and therapeutic potential of CAN-3110 in the Ras-Raf pathway altered melanoma model. The data will be presented at the Society for ...

Their research increased our knowledge of the pathway – known as the RAS/RAF/MEK/ERK pathway – and its role in cancer, and helped identify targets for new classes of cancer drugs. Building on this ...

RTKs can activate Ras, a protein that is tethered to the plasma membrane, by causing it to bind GTP. Once activated, Ras can do a variety of things. In this example, it activates an enzymatic ...